Genesis Therapeutics vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Genesis Therapeutics (now Genesis Molecular AI) is a biotech company applying AI to small molecule drug discovery; raised $200M Series B in 2025 led by Andreessen Horowitz, Fidelity, BlackRock, and NVIDIA;
About
Genesis Therapeutics — now operating as Genesis Molecular AI — is a clinical-stage biotechnology company founded in 2019 and headquartered in Burlingame, California. The company applies artificial intelligence and machine learning to the discovery and optimization of small molecule drug candidates, with a focus on targets that have historically been considered intractable or undruggable by conventional computational chemistry approaches. Its proprietary platform, GEMS (Genesis Exploration of Molecular Space), uses deep learning to navigate the vast chemical space of possible drug-like molecules, identifying novel compounds with high predicted potency, selectivity, and drug-like properties against disease-relevant protein targets.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Genesis Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.